Robert Legler, MD
Internal Medicine · Parsons, KSNPI 1811128598
Payments from drug & device makers
Across 215 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$420
- AbbVie$335
- Lilly USA, LLC$246
- Pfizer$216
- Amgen$188
- Novo Nordisk$167
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,23199%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $420 |
| AbbVie(2 entities) | 30 | $335 |
| Lilly USA, LLC | 18 | $246 |
| Pfizer | 16 | $216 |
| Amgen | 12 | $188 |
| Novo Nordisk | 11 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $160 |
| Sanofi-aventis U.S. LLC | 11 | $146 |
| GSK | 10 | $145 |
| Boehringer Ingelheim | 10 | $136 |
| LNHC, Inc | 1 | $130 |
| Merck | 7 | $94 |
| Astellas Pharma US Inc | 5 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $72 |
| Novartis | 4 | $69 |
| Corium, LLC | 4 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $45 |
| Bayer | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 3 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Ardelyx, Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| Abbott | 1 | $22 |
| Dexcom, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
| Adamas Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZELSUVMI$130
How this compares
$3,251 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $131,150 |
| FarxigaDapagliflozin Propanediol | 125 | $95,506 |
| JardianceEmpagliflozin | 93 | $92,345 |
| XeljanzTofacitinib Citrate | 13 | $84,804 |
| MounjaroTirzepatide | 57 | $69,480 |
| EliquisApixaban | 114 | $61,462 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $46,749 |
| LinzessLinaclotide | 102 | $44,011 |
| TrulicityDulaglutide | 45 | $42,779 |
| RexultiBrexpiprazole | 25 | $38,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,123 |
| JanuviaSitagliptin Phosphate | 39 | $35,959 |
| TradjentaLinagliptin | 34 | $35,863 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $29,127 |
| ViberziEluxadoline | 18 | $28,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $167 | $157,173141 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $420 | $146,603191 claims |
| PfizerXeljanz, Eliquis | $216 | $146,266127 claims |
| Boehringer IngelheimJardiance, Tradjenta | $136 | $128,208127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $246 | $112,259102 claims |
| AbbVieLinzess, Viberzi, Creon | $335 | $83,368138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $145 | $48,58672 claims |
| MerckJanuvia, Belsomra | $94 | $40,60550 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36 | $38,70425 claims |
| Johnson & JohnsonXarelto | $29 | $22,38526 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $15,90848 claims |
| NovartisEntresto | $69 | $10,92414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Parsons
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
- Kyle WorkKansas City$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.